• Raised A$38.5M through private placement to existing and new investors
• Funds will advance the PARADIGM global pivotal trial for DurAVR® Transcatheter Heart Valve
• Also expand manufacturing capabilities and fund ongoing R&D for v2vmedtech

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) announced a ~A$38.5 million / (US$25.2 million) private placement through the issuance of 5,135,000 shares and CDIs. The funds will be used to support the next stage of growth and advance execution of the company's clinical strategy, including recruitment to the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with aortic stenosis (the PARADIGM Trial), effective study execution, and expansion of manufacturing capabilities. A portion of the proceeds will also fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes. The placement was strongly supported by existing shareholders and new investor Second Line Capital Management LLC. Anticipated milestones include expansion of the PARADIGM Trial to additional countries and sites, IDE approval from the FDA, and strategic deployment of capital into critical infrastructure like diversified ADAPT tissue sourcing channels.